Cambridge (UK) based Antitope, a subsidiary of Abzena, has signed an agreement to collaborate with Synthon Biopharmaceuticals, a global pharmaceutical company based in Nijmegen, the Netherlands.
Synthon, with expertise in the development of complex small molecule and biosimilar drugs and new biopharmaceuticals, including antibody drug conjugates or ADCs, will use Antitope’s experience to assess the potential immunogenicity of candidate antibodies for Synthon’s ADC programmes.
Antitope will use its EpiScreen™ technology, a highly accurate and sensitive ex vivo human T cell assay to determine the potential immunogenicity of the antibodies provided by Synthon.
The EpiScreen™ technology is an accurate and sensitive way to assess the potential immunogenicity of proteins and antibodies ex vivo by measuring CD4+ T cell responses[1], the primary drivers of memory-based immunogenicity. These technologies are used extensively across the industry as a standard for preclinical immunogenicity testing.
The technology correlates with published clinical anti-drug antibody immunogenicity data which supports selection of lead product candidates with low immunogenicity during preclinical development.
“We are confident that Antitope’s EpiScreen™ technology will strongly help reduce the risk that Synthon’s antibody based development candidates will induce immunogenic responses in patient populations,” noted Marco Timmers, CSO of Synthon Biopharmaceuticals.
“We are very pleased to be working with a company that, like Abzena, has scientific innovation at the heart of its business and look forward to collaborating with Synthon to help it build its biopharmaceuticals pipeline,” said Matthew Baker, CSO of the Abzena group and co-founder of Antitope.
Last Editorial Review: July 2, 2014
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
